We serve Chemical Name:2-(3-methylbenzyl)-1,3,4-oxadiazole CAS:1026573-04-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(3-methylbenzyl)-1,3,4-oxadiazole
CAS.NO:1026573-04-5
Synonyms:2-(3-Methylbenzyl)-1,3,4-oxadiazole;1,3,4-Oxadiazole, 2-[(3-methylphenyl)methyl]-
Molecular Formula:C10H10N2O
Molecular Weight:174.199
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:301.5±45.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.546
PSA:38.92000
Exact Mass:174.079315
LogP:1.75
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(3-Methylbenzyl)-1,3,4-oxadiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3,4-Oxadiazole, 2-[(3-methylphenyl)methyl]- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3,4-Oxadiazole, 2-[(3-methylphenyl)methyl]- Use and application,2-(3-Methylbenzyl)-1,3,4-oxadiazole technical grade,usp/ep/jp grade.
Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2-(3-methylbenzyl)-1,3,4-oxadiazole manufacturer Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections. 2-(3-methylbenzyl)-1,3,4-oxadiazole supplier In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. 2-(3-methylbenzyl)-1,3,4-oxadiazole vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2-(3-methylbenzyl)-1,3,4-oxadiazole factory The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said study first author Dr. Susan Domchek, executive director of the Basser Center for BRCA at the University of Pennsylvania’s Perelman School of Medicine.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes.
“We shouldn’t make changes to testing guidelines based on race alone,” she said in a university news release. “Rather, our efforts should focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes.
